28 citations,
August 2003 in “Steroids” Hirsute women have lower type 2 17β-HSD enzyme levels, which improve with treatment.
20 citations,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
19 citations,
March 2010 in “Bioorganic & Medicinal Chemistry Letters” Curcumin and its derivatives can block an enzyme important for making testosterone, with one derivative being particularly strong.
14 citations,
May 2005 in “Steroids” A new method was developed to make finasteride for treating hair loss.
14 citations,
February 1994 in “Tetrahedron Letters” Adding cerium(III) chloride to Grignard reagents improves the making of compounds that could treat prostate issues and hair loss.
13 citations,
September 1986 in “Archives of Dermatology” Women with more 3α,17β-androstanediol glucuronide compared to sex hormone binding globulin are more likely to have female pattern baldness.
10 citations,
August 1998 in “Journal of Investigative Dermatology” The compounds tested could potentially treat hair loss and alopecia.
6 citations,
January 2017 in “Annals of Dermatology” Combination of 17α-estradiol and minoxidil improves hair growth and reduces hair loss in most patients.
Potential new drugs for treating PCOS were identified.
January 2024 in “International journal of molecular sciences” A brain-made hormone can protect against memory-related brain damage caused by harmful proteins.
April 2023 in “Journal of Investigative Dermatology” Type 1/17 inflammation in psoriasis increases skin cell growth due to a molecule that could be a new treatment target.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
June 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” 17α-estradiol extends lifespan and improves metabolism in male mice through the estrogen receptor α.
March 2020 in “Annals of internal medicine” Monitor methotrexate side effects, research cannabis treatments, and use mycophenolate mofetil for lupus nephritis.
51 citations,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
21 citations,
January 2012 in “Annals of Dermatology” 17α-Estradiol solution safely improves hair density and thickness in female pattern hair loss.
17 citations,
August 2015 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” The study found that urine metabolites M1b or M4 are the best indicators of ATD use in horses, with detection possible up to 77 hours in urine and 28 hours in blood.
6 citations,
July 2007 in “Organic Process Research & Development” Alcoholic solvent improves selectivity in key intermediate for finasteride and dutasteride synthesis.
5 citations,
February 1997 in “Bioorganic & Medicinal Chemistry” New compounds were made that effectively block a specific enzyme related to androgen conditions.
4 citations,
April 2020 in “Dermatology practical & conceptual” Topical finasteride works faster and better than 17α-estradiol for postmenopausal hair loss.
3 citations,
May 2017 in “Bioorganic & medicinal chemistry letters” New compounds were made that are promising for prostate cancer therapy.
2 citations,
December 2008 in “Journal of Chemical Crystallography” The research shows that hydrogen bonds greatly affect the crystal structure of a Finasteride derivative.
2 citations,
October 2001 in “Analytical Sciences” A new compound that could treat various androgen-related conditions was created and analyzed.
1 citations,
January 2009 in “X-ray Structure Analysis Online” A new compound was made that might help treat diseases related to male hormones.
January 2022 in “Consultant” September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
June 2010 in “Journal of Chemical Crystallography” The compound was successfully made and shows potential for treating prostate cancer.
January 2004 in “Analytical Sciences: X-ray Structure Analysis Online” The document explains how to make a compound called 3.BETA.-Benzoyloxy-4-pregnen-16.ALPHA.,17.ALPHA.-epoxy-6,20-dione and describes its crystal structure.
August 2002 in “Analytical Sciences” The document concludes that a compound with potential for treating prostate cancer and hair loss was successfully made and its detailed structure was confirmed.
179 citations,
May 1982 in “The Journal of clinical investigation/The journal of clinical investigation” High levels of 3 alpha-diol glucuronide in the blood are a marker of increased androgen action in women with excessive hair growth of unknown cause.